BIO- MEDICAL/THERAPEUTIC IDEAS
ARE THE FOUNDATIONS OF CURE FROM A HUMAN DISEASE
BIO- MEDICAL/THERAPEUTIC IDEAS
ARE THE FOUNDATIONS OF CURE FROM A HUMAN DISEASE
BIO- MEDICAL/THERAPEUTIC IDEAS
ARE THE FOUNDATIONS OF CURE FROM A HUMAN DISEASE
Total No of Ideas : 11717
LncRNA-based regenerative cardiovascular therapy: Sirtuin 5 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 14/December/2021, 6.38 amhttps://genomediscovery.org/wp-content/uploads/2021/12/Sirtuin5-based-therapy-improves-functional-recovery-after-Myocardial-infarction.jpg-2.jpg960720https://genomediscovery.org/wp-content/uploads/2021/12/Sirtuin5-based-therapy-improves-functional-recovery-after-Myocardial-infarction.jpg-2.jpg
What they say: A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of the journal Nature, by Profs. Stefanie Dimmeler (Director, Center for Molecular Medicine), Reinier A Boon and others. What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist…
Molecular therapy for safeguarding your heart against cardiac dysfunction: MiR-488-5p-based therapy for cardiomyocyte proliferation and heart regeneration: MiR-488-5p decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 22/October/2021, 12.07 pmhttps://genomediscovery.org/wp-content/uploads/2021/12/MiR-488-5p-based-therapy-for-preventing-cardiac-hypertrophy-and-fibrosis-.jpg1_.jpg960720https://genomediscovery.org/wp-content/uploads/2021/12/MiR-488-5p-based-therapy-for-preventing-cardiac-hypertrophy-and-fibrosis-.jpg1_.jpg
Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China; and Department of Pathology and Laboratory Medicine, University…
LncRNA-based regenerative cardiovascular therapy: LncRNA RMRP inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 1/November/2021, 5.23 pmhttps://genomediscovery.org/wp-content/uploads/2021/11/LncRNA-RMRP-based-therapy-improves-functional-recovery-after-Myocardial-infarction.jpg960720https://genomediscovery.org/wp-content/uploads/2021/11/LncRNA-RMRP-based-therapy-improves-functional-recovery-after-Myocardial-infarction.jpg
What they say: A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of the journal Nature, by Profs. Stefanie Dimmeler (Director, Center for Molecular Medicine), Reinier A Boon and others. What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist…
LncRNA-based regenerative cardiovascular therapy: LncRNA βFaar inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 22/October/2021, 11.33 amhttps://genomediscovery.org/wp-content/uploads/2021/10/LncRNA-βFaar-based-therapy-improves-functional-recovery-after-Myocardial-infarction-1.jpg1_-1.jpg960720https://genomediscovery.org/wp-content/uploads/2021/10/LncRNA-βFaar-based-therapy-improves-functional-recovery-after-Myocardial-infarction-1.jpg1_-1.jpg
What they say: A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of the journal Nature, by Profs. Stefanie Dimmeler (Director, Center for Molecular Medicine), Reinier A Boon and others. What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist…
MiRNA-488-5p inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 14/December/2021, 7.07 amhttps://genomediscovery.org/wp-content/uploads/2021/10/MiR-488-5p-based-therapy-improves-functional-recovery-after-Myocardial-infarction.jpg-2.jpg960720https://genomediscovery.org/wp-content/uploads/2021/10/MiR-488-5p-based-therapy-improves-functional-recovery-after-Myocardial-infarction.jpg-2.jpg
What they say: A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of the journal Nature, by Profs. Stefanie Dimmeler (Director, Center for Molecular Medicine), Reinier A Boon and others. What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief…
Molecular therapy for safeguarding your heart against cardiac dysfunction: lncRNA βFaar-based therapy for cardiomyocyte proliferation and heart regeneration: lncRNA βFaar decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 22/October/2021, 11.33 amhttps://genomediscovery.org/wp-content/uploads/2021/10/LncRNA-βFaar-based-therapy-for-preventing-cardiac-hypertrophy-and-fibrosis-.jpg960720https://genomediscovery.org/wp-content/uploads/2021/10/LncRNA-βFaar-based-therapy-for-preventing-cardiac-hypertrophy-and-fibrosis-.jpg
Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China; and Department of Pathology and Laboratory Medicine, University…
Realize Your Full PotentialStart nowThe future is changing with usContact usOrganize Your LifeLet’s go
Previous
Next
“Help us make a difference by supporting our mission with your generous donation.”
Welcome to Genomediscovery
<href=”/home”>
ABOUT US
Who we are and what we do
Ideas can even be life changing.
We generate bio-medical/pharma/therapeutic/clinical ideas for the scientific community. Good Ideas are uncommon and unique. This is because everyone’s educational background is different. As a result, every one’s thinking process is different. Consequently, his/her ability to connect/understand complex biological/pathological mechanism differs.
This template has beautifull and unique design that will be best suited for your online web presence, the theme also responsive.
We Are Trusted
This template has beautifull and unique design that will be best suited for your online web presence, the theme also responsive.
We Are Expert
This template has beautifull and unique design that will be best suited for your online web presence, the theme also responsive.
Dr L. Boominathan Ph.D.
President & Director-cum-Chief scientist
Dr Boominathan was the first one in the world to propose a p73/p63-dependent cancer suppressor pathway (Supported by a legally valid Invention disclosure document certified by an advocate-2002/3)
0
+
Total Ideas
0
+
Last Year Visitor count
0
+
Research Paper Published
OUR MISSION
Research
To provide bio-medical/pharma/therapeutic ideas to Scientists/Researchers/Physicians/Medical Professionals
To develop miRNA/Natural product-based therapeutics
To develop Longevity medicines
To review research articles for authors/journals
To provide consultancy to Biotechnology pharmaceutical companies/universities/IITs/INSERs/NITs
To organize meetings/conferences/symposia
Education
To offer M.S programs in Cancer Biology, Stem cell Biology & Regenerative Medicine, Molecular Medicine, Genome Biology & Bio-Medical Sciences. Refer B-MERIT for details
To provide guidance to increase research productivity of state universities/private/medical colleges
To provide research project training
What Scientists Say’s ?
“reports are very reliable and he is a hard-worker and very devoted to his research”
Dr.Varda Rotter, Ph.D.,
Professor & Head of the Dept, Dept of Molecular cell Biology, The Weizmann Institute of Science, Rehovot, Israel
“I was impressed with his (Dr L Boominathan) knowledge and ideas in the field of p53, of RNA…”
Prof. Dr. Lea Eisenbach, Ph.D.,
Dept of Molecular cell Biology, The Weizmann Institute of Science, Rehovot, Israel
If you need industrial solution, We are available for you
We provide innovative solutions for sustainable progress. Our professional team works to increase productivity and cost effectiveness on the market
